New bone-building drugs for osteoporosis

Escrito por: Professor David Reid
Publicado: | Actualizado: 14/12/2023
Editado por: Emma McLeod

Our bones can become weak and brittle over time. This occurs when the body produces too few bone cells, which ultimately reduces overall bone density.

 

In the past, it was only possible to stop further loss of bone density. Now, with newer drugs, it’s possible to regain some of this loss.

 

This article explains how these new bone-building drugs work and how they differ from older ones.

 

A doctor is holding up an x-ray image of the hip region. He is pointing to it and explaining it to a patient.

 

How do bone-building drugs for osteoporosis work?

 

Most drugs for treating osteoporosis work by inhibiting or stopping the breakdown of bone, while at the same time, allowing the formation of the new bone cells.

 

Now, new bone-building drugs do the reverse – they encourage the cells (called osteoblasts) to lay down the new bone that would eventually encourage cells that break down bone to work harder. They increase the formation of new bone quite rapidly, while not increasing nearly so much of the breakdown of bone.

 

It’s important to note that there is an imbalance for a short time between the rate of formation and breakdown, but this balances out over time. About six to twelve months after taking these new osteoporosis drugs, you will be getting a significant increase in bone density.

 

Older bone-building drugs

The older drug for osteoporosis is typically known as Teriparatide and it is currently the only one available in the UK. This is injected once every day for a maximum of 24 months.

 

Newer bone-building drugs

Evenity, a new bone-building drug for osteoporosis, is now licensed in the UK and is currently set to become available in early 2020. This is injected once a month for 12 months.

 

What increase in bone density can be expected after taking bone-building drugs?

 

In the spine, you can expect an increase in bone density of about 10-15% over one to two years, depending on the drug. Evenity, the newer drug, offers better results at a slightly faster pace.

 

At the hips, Evenity can increase hip bone density by 3-4%. Usually, Teriparatide doesn’t increase hip bone density enough to be measurable.

 

Who is the ideal candidate?

 

To be eligible, you need a very low bone density. It must be low enough to be considered osteoporosis.

 

Furthermore, both old and new bone-building drugs should primarily be used in those who have had a spine fracture or are at the highest risk of a spine fracture. This is because those who have experienced a spinal fracture are highly susceptible to another, and these drugs are very effective in preventing them.

 

Age and gender do not affect a person’s risk of osteoporosis. The new bone-building drug, however, will only be licensed initially for post-menopausal women. Younger women have a very low chance of needing them unless they’ve had an eating disorder or an exceptional condition which has increased their risk of osteoporosis at a young age.

 

Are bone-building drugs safe? Do the risks outweigh the cons of not taking the drugs?

 

In general, they are safe, as long as you’ve met the criteria - that is, that you are a woman with very low bone density and at a high risk of a spinal fracture.

 

Regarding the older bone-building drugs, they can increase the calcium level in your blood. Therefore, if you already have a high level of calcium in your blood, your rheumatologist may advise against taking it.

 

For the new drug, Evenity, those who have had a heart attack or stroke within the previous year shouldn’t take it. In this case, taking the drug would mean the risks outweigh the potential side effects.

 

Overall, side-effects are rare and consist of general side effects of injections such as local upset and local irritation. While the extremely rare side-effects of osteonecrosis of the jaw and atypical femur fractures seen with other osteoporosis drugs have been reported in those taking Evenity, it is unlikely that the new drug is actually causing those.

 

Are there alternatives to drugs for those who don’t want to take them but want to increase bone density?

 

You can’t reliably increase bone density through lifestyle measures. Weight-bearing exercises have the potential to assist in slowing or stopping a loss of bone density, but it’s not generally possible to increase it through these means.

 

Whereas, with medical treatment for osteoporosis, the likelihood that you’ll receive a significant increase in bone density is much, much higher. From March 2020, when the new bone-building drug becomes available, there is the potential to regain some of your lost bone density.

 

 

Professor David Reid is a leading international expert in the assessment and treatment of osteoporosis. Visit Professor Reid’s Top Doctors profile to book a consultation and discover how he can assist you in looking after your bone health.

Professor David Reid

Por Professor David Reid
Reumatología

El profesor David Reid es un experto reumatólogo consultor en Londres , cuya área de especialización radica en la prevención y el tratamiento de la osteoporosis y DEXA (escaneo de densidad ósea). También tiene experiencia a largo plazo en el manejo de la artritis reumatoide, la osteoartritis, la gota y la polimialgia . Ha sido pionero en la aplicación clínica del escaneo de rayos X de doble energía (DEXA) y es un experto internacional líder en la evaluación y el tratamiento de la osteoporosis .

Es profesor emérito de Reumatología en la Universidad de Aberdeen y fue director de la Facultad de Medicina y Odontología de la universidad.
Es autor de más de 300 artículos y revisiones originales sobre sus intereses de investigación, que incluyen la utilidad de la evaluación de la masa ósea, la evaluación del riesgo de fractura, la osteoporosis secundaria y los efectos adversos de los medicamentos en las enfermedades reumáticas.

Fue presidente de la Junta de Síndicos de la Sociedad Nacional de Osteoporosis del Reino Unido de 2008 a 2012 y anteriormente presidió su Comité de Subvenciones para Investigación y su Junta Médica. Hasta finales de 2013, fue Presidente del Grupo de Estudios Clínicos de Arthritis Research UK con la responsabilidad de asesorar sobre las necesidades de ensayos clínicos en enfermedades óseas. El profesor Reid es un embajador voluntario de la Sociedad Nacional de Osteoporosis.


  • Tratamientos relacionados
  • Ozone therapy
    Neuropathic pain
    Vasculitis
    Elbow Pain
    Bursitis
    Knee osteoarthritis
    Growth factors
    Trapped nerve
    Spinal osteoarthritis
    Spine fracture
    Este sitio web utiliza Cookies propias y de terceros para recopilar información con la finalidad de mejorar nuestros servicios, para mostrarle publicidad relacionada con sus preferencias, así como analizar sus hábitos de navegación. El usuario tiene la posibilidad de configurar sus preferencias AQUI.